Table 8.
Body weight gain (BWG) and histomoniasis-related mortalities during Vaccination and Challenge Phases (Experiment 4).1
| Vaccination phase |
Challenge phase |
||||
|---|---|---|---|---|---|
| Group2,3 | d 14–28 Mortality | d 28–35 Mortality4 | d 13–34 BWG (g) | d 35–49 Mortality | d 34–49 BWG (g) |
| PC Buford | 25/60 (41.7%) | 14/35 (40.0%) | 682 ± 86.4b | 24/39 (61.5%) | 647 ± 112c |
| Vacc PHL P67 | 0/59 (0.00%)* | 0/49 (0.00%)* | 901 ± 15.6a | 8/39 (20.5%)* | 1090 ± 76.7ab |
| Vacc PHL P129 | 0/60 (0.00%)* | 0/50 (0.00%)* | 917 ± 16.8a | 9/40 (22.5%)* | 893 ± 85.6bc |
| Vacc Buford P80a | 0/60 (0.00%)* | 0/50 (0.00%)* | 861 ± 16.0a | 7/40 (17.5%)* | 937 ± 88.4bc |
| Vacc Buford P200a | 0/60 (0.00%)* | 0/50 (0.00%)* | 898 ± 15.1a | 3/40 (7.50%)* | 931 ± 62.0bc |
| Vacc Buford P138b | 0/59 (0.00%)* | 0/49 (0.00%)* | 909 ± 13.4a | 12/39 (30.8%)* | 899 ± 68.5bc |
| Vacc Buford P198c | 0/60 (0.00%)* | 0/50 (0.00%)* | 874 ± 18.0a | 7/40 (17.5%)* | 1000 ± 76.5abc |
| NC | 0/69 (0.00%)* | 0/59 (0.00%)* | 888 ± 13.8a | 0/20 (0.00%)* | 1359 ± 33.5a |
BWG data are expressed as mean ± SE; Values within a column with no common superscript differ significantly (P < 0.05). Data were analyzed using JMP Pro 16 ANOVA, further separated by Tukey's HSD.
Vaccination Phase consisted of intracloacal administration of 2 × 105 cells/turkey of either Vacc (PHL2017 or Buford isolates of passage indicated) or Buford WTH cells/turkey on d 14; Challenge Phase began on d 35 with the intracloacal administration of 2 × 105 Buford WTH cells/turkey to the Vacc and PC groups (new PC Buford formed from subset of the NC).
NC, non-challenged control; PC, positive-challenged control, Vacc, live-attenuated Histomonas meleagridis; WTH, wild-type H. meleagridis.
Isolates of H. meleagridis: Buford strain (isolated from infected chickens in Georgia); PHL2017 strain (isolated from infected turkeys in Arkansas); Passage number and isolate indicator follow each group name.
Adjusted for remaining n/group after d 28 lesion score subset.
Indicates significant difference in mortalities (P < 0.05) as compared to the respective Vaccination or Challenge Phase PC Buford group with chi-square test.